UBS Group
CAMP icon

UBS Group’s CAMP4 Therapeutics CAMP Stock Holding History

UBS Group’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.4K Buy
11,525
+2,444
+27% +$10.5K ﹤0.01% 7558
2026
Q1 		$40K Buy
9,081
+3,936
+77% +$18.7K ﹤0.01% 7520
2025
Q4 		$31.5K Sell
5,145
-1,898
-27% -$8.07K ﹤0.01% 7498
2025
Q3 		$21.1K Buy
7,043
+1,955
+38% +$3.62K ﹤0.01% 8118
2025
Q2 		$7.38K Buy
5,088
+1,905
+60% +$3.79K ﹤0.01% 9019
2025
Q1 		$12.7K Sell
3,183
-7,125
-69% -$34.5K ﹤0.01% 8482
2024
Q4 		$53.8K Buy
+10,308
New +$84.7K ﹤0.01% 7255

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's CAMP Position: Q2 2026 in Review

UBS Group increased its CAMP4 Therapeutics (CAMP) stake by 27% in Q2 2026, buying an estimated $10.5K and bringing the position to 11,525 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #7558.

UBS Group first reported a position in CAMP in Q4 2024 and has held it in 7 quarters since. The position peaked at $53.8K in Q4 2024. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • UBS Group held 11,525 shares of CAMP4 Therapeutics worth $50.4K as of Q2 2026.
  • UBS Group bought 2,444 CAMP4 Therapeutics shares in Q2 2026, an estimated $10.5K.
  • CAMP4 Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7558 holding.
  • UBS Group first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • UBS Group's CAMP4 Therapeutics position peaked at $53.8K in Q4 2024.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.